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Investigation of HNF-1B as a diagnostic
biomarker for pancreatic ductal
adenocarcinoma
Michelle X. Yang1,7*, Ryan F. Coates1, Abiy Ambaye1, Juli-Anne Gardner1, Richard Zubarick2, Yuan Gao3,
Joan Skelly4, James G. Liu5 and Mari Mino-Kenudson6
Abstract
Background: Diagnosing pancreatic ductal adenocarcinoma (PDAC) in the setting of metastasis with an unknown
primary remains very challenging due to the lack of specific biomarkers. HNF-1B has been characterized as an important
transcription factor for pancreatic development and was reported as a biomarker for clear cell subtype of PDAC.
Methods: To investigate the diagnostic role of HNF-1B for PDAC, we used tissue microarray (TMA) and
immunohistochemistry (IHC) to characterize HNF-1B expression in a large cohort of carcinomas, including 127
primary PDACs, 47 biliary adenocarcinomas, 17 metastatic PDACs, and 231 non-pancreaticobiliary carcinomas.
Results: HNF-1B was expressed in 107 of 127 (84.3%) of PDACs, 13 of 15 (86.7%) of cholangiocarcinomas, 13
of 18 (72%) of ampullary carcinomas, and 13 of 14 (92.9%) of gallbladder adenocarcinomas. Notably, HNF-1B
was expressed in 16 of 17 (94.1%) of metastatic PDACs. Among the non-pancreaticobiliary cancers, HNF-1B was expressed
in ~ 77% clear cell carcinomas of the kidney and ovarian clear cell carcinomas. Gastroesophageal, lung, and prostate
adenocarcinomas occasionally expressed HNF-1B in up to 37% cases. HNF-1B was completely negative in hepatocellular,
colorectal, breast, and lung squamous cell carcinomas. The sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy of HNF-1B for primary pancreaticobiliary carcinoma is 84, 68, 66, 85, and 75%,
respectively. HNF-1B expression was not significantly associated with overall survival in patients with PDAC, but tumor
size ≥2 cm and high tumor grade were significantly associated with worse overall survival in multivariate analyses.
Conclusions: HNF-1B may be used in surgical pathology to aid the diagnosis of metastatic pancreatic and biliary
carcinoma with a panel of other markers to exclude lung, kidney, prostate, and Müllerian origins.
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Background
Pancreatic ductal adenocarcinoma (PDAC) consists of
approximately 85% of cancers arising in the pancreas,
and is one of the most lethal malignancies in the world.
Despite new generations of neoadjuvant and adjuvant
therapies, the 5-year overall survival rate remains less
than 5%, and patients with PDAC often present with
metastatic disease of an unknown primary [1, 2]. An ac-
curate diagnosis of PDAC on biopsy specimens remains
challenging due to the lack of specific biomarkers [3, 4].
Investigating additional markers to improve the diagno-
sis of PDAC is of paramount important in daily practice
for surgical pathologists.
Hepatocyte nuclear factor 1B (HNF-1B) has been
well-characterized as one of the transcription factors in-
volved in the early development of liver, pancreas, and
kidney [5–7]. In animal models, HNF-1B gene was re-
quired for the morphogenesis of both ventral and dorsal
pancreatic buds [8, 9]. In human subjects, mutations in
HNF-1B caused severe pancreatic agenesis or hypoplasia,
maturity-onset diabetes of the young (MODY) type 5, multi-
cystic renal dysplasia, and hepatobiliary tract and Müllerian
tract abnormalities [10–14]. In human adenocarcinomas,
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HNF-1B was highly expressed in ovarian clear cell carcin-
omas and has been recognized as a useful molecular bio-
marker for this entity [15–17]. Interestingly, a recent study
showed that PDAC with clear cell morphology strongly
expressed HNF-1B, in contrast to the conventional type
PDAC with only weak (61%) to moderate (24%) staining
[18]. Due to the essential role of HNF-1B in pancreatic de-
velopment, we hypothesized that HNF-1B was expressed in
all cancers arising from the pancreatic ductal epithelium re-
gardless of the histomorphology, and its expression may
serve as a diagnostic marker of these cancers. Using immu-
nohistochemistry (IHC) and tissue microarray (TMA), we
investigated HNF-1B protein expression in 127 primary
PDACs, 47 biliary tract adenocarcinomas, 17 metastatic
PDACs, and 231 common non-pancreaticobiliary carcin-
omas, and calculated its sensitivity and specificity. The utility




A total of 127 primary PDAC resections and 17 known
metastatic PDACs were retrospectively retrieved from for-
malin fixed paraffin embedded (FFPE) blocks. Among the
127 primary PDACs, 10 cases received neoadjuvant therapy
and 112 cases had negative resection margins (R0). A total
of 85 cases had complete survival data with at least 2 years
of follow-up after resection. Among the 17 metastatic
PDACs, metastatic sites included liver (N = 13), celiac
lymph nodes (N = 2), peritoneum (N = 1), and bone (N = 1).
In addition, 47 adenocarcinomas from the biliary tract and
231 non-pancreaticobiliary carcinomas that morphologic-
ally mimic PDAC (mimickers) were also evaluated for com-
parison, including those of the ampulla, intrahepatic and
extrahepatic biliary tract, gallbladder, colorectal, esophagus,
stomach, hepatocellular carcinoma, lung (both adenocar-
cinoma and squamous cell carcinoma), bladder (urothelial
carcinoma), breast (ductal and lobular), kidney (mainly
clear cell carcinoma), prostate, ovarian surface epithelial,
and endometrial. This study was approved by our Institu-
tional Review Board (IRB # 17–0009).
Histological evaluation and tissue microarray (TMA)
construction
All tumor slides of the 127 primary PDAC resections
were reviewed, and the size of the tumor, tumor (pT)
and nodal (pN) stages, tumor grade, tumor morphology
(cytoplasmic clearing), lymphovascular invasion (LVI),
perineural invasion (PNI), and resection margin status
were extracted from the electronic pathologic record.
The death status were extracted from the Tumor Regis-
try data set. The final stage of PDAC was diagnosed in
accordance with the American Joint Committee on Can-
cer (AJCC), 7th edition [19]. Two-millimeter core TMAs
were constructed with two cores each from the FFPE
tumor tissue or adjacent non-neoplastic pancreas (as con-
trol) of primary PDAC resections or 278 non-pancreatic
cancers (Beecher Instruments Inc., Sun Prairie, WI).
Eleven of 17 metastatic PDACs were also included in the
duplicated 2-mm core TMA, and the remaining 6 meta-
static PDACs were biopsies that were mounted onto indi-
vidual slides.
Immunohistochemistry (IHC)
Polyclonal anti-HNF-1B (Sigma, St. Louis, MO, HPA002083,
1:200 dilutions) was validated in non-neoplastic pancreatic
tissue sections. Antigen retrieval was obtained for HNF-1B
in H1 buffer (Leica Biosystems, Buffalo Grove, IL) for
10 min, All IHCs were performed in Leica BOND-III auto-
mated IHC stainer. Localization of staining – nuclear, cyto-
plasmic and/or membranous – was recorded in each case,
and the case was recorded as positive if any amount of
tumor cells had any pattern of HNF-1B expression. A
two-tier scale was applied to all positive cases for HNF-1B:
“strong”, if the stain was clearly visualized at 20× low magni-
fication, and “weak”, if the stain was clearly visualized at
100× magnification with less intensity.
As comparison, a monoclonal antibody (Abnova, clone
CL0374, 1:200 dilution) was validated under the same
conditions mentioned above and showed nuclear reactiv-
ity in normal pancreatic ductal epithelium, but not in
the acinar cells or islet cells, which was consistent with
the result of polyclonal antibody. All cancer TMAs were
investigated with the HNF-1B expression using the poly-
clonal antibody.
Statistical analysis
All demographic and clinicopathological measures were
screened for ranges and appropriate codes. Eighty five of
the 127 primary PDAC patients had complete demographic
and clinicopathological measures and had survival data
with at least 2 years of follow-up after the resection. For
these 85 patients, descriptive statistics for these measures
were calculated. The association between HNF-1B protein
expression and clinicopathological features was examined
using 2 × 2 contingency tables with Fisher’s extract tests.
Univariate Cox proportional hazard function models were
used to examine the association of each of the clinicopatho-
logical measures with overall survival. The significant mea-
sures were included in a stepwise modeling procedure to
determine a final model. The expression rate of HNF-1B in
PDAC was compared to the rate in each of the other cancer
types using Fisher’s exact tests. The sensitivity, specificity
and other measures of HNF-1B in classifying pancreatico-
biliary and non-pancreaticobiliary carcinomas were calcu-
lated with 95% confidence intervals. All statistical analyses
were conducted using SAS 9.3 software (SAS Institute, Cary
NC). Statistical significant was determined by P < .05.
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Results
Demographics and clinicopathologic features of PDAC
Among the 85 primary PDAC patients with complete clin-
icopathologic data, the mean age was 65 years (SD = 10),
55 were male (65%) (Table 1). Sixty eight (80%) had posi-
tive HNF-1B expression. Fisher’s exact tests found no sig-
nificant associations between HNF-1B expression and the
clinicopathologic parameters. In univariate analysis, only
tumor size ≥2 cm (P = .03) and high tumor grade
(P = .02) were significantly associated with worse overall
survival. HNF-1B protein expression did not demonstrate
significant association with the overall survival. In multi-
variate analysis, tumor size ≥2 cm (P = .03) and high
tumor grade (P = .02) remained significantly associated
with worse overall survival (Table 2).
HNF-1B expression in non-neoplastic pancreatic and
biliary epithelium
In non-neoplastic adult pancreas, HNF-1B was expressed in
the ductal epithelium and centroacinar ductal cells with pre-
dominant nuclear and faint cytoplasmic staining (Fig. 1a).
Since HNF-1B is also a transcription factor for liver deve-
lopment, we investigated HNF-1B immunostaining in nor-
mal liver and gallbladder. Interestingly, HNF-1B showed
predominant nuclear staining in the gallbladder epithelium
(Fig. 1b), in contrast to a predominant cytoplasmic staining
in non-neoplastic intrahepatic ductal and extrahepatic
ductal epithelium (Fig. 1c).
Morphological variation of primary and metastatic PDAC
In a previous study, Kim et al. reported that HNF-1B was
strongly expressed in PDAC with cytoplasmic clearing and
only weakly to moderately expressed in PDAC with con-
ventional histomorphology.18 We reviewed the morphology
specifically the cytoplasmic clearing for all the PDAC cases
in this cohort and separated them into 3 categories: 1) Con-
ventional- if > 95% of tumors cells demonstrated no cyto-
plasmic clearing (Fig. 2a); 2) Prominent clearing- if > 75%
tumor cells demonstrated cytoplasmic clearing (Fig. 2b);
and 3) mixed features- if 5–75% tumor cells demonstrated
cytoplasmic clearing (Fig. 2c). Among the 127 primary
PDACs, 84 cases (66.1%) were conventional PDAC, and 43
cases (33.9%) showed variable cytoplasmic clearing in the
tumor cells, including 10 cases (7.9%) with prominent clear-
ing, and 33 cases (26%) with mixed features. In 17 meta-
static PDACs, 1 case showed prominent cytoplasmic
clearing, 2 cases had mixed features, and the remaining
showed conventional morphology.
Variable expression pattern of HNF-1B in primary and
metastatic PDAC
Although HNF-1B was characterized as a nuclear tran-
scription factor, HNF-1B was expressed in a total of 107
(84.3%) PDACs with multiple staining patterns, including
Table 1 Demographics and clinicopathological parameters in
patients with PDAC
Variables PDAC (N = 85)





≤ 2 cm 18 (21%)




LN metastasis 54 (64%)
LVI 40 (48%)
PNI 61 (72%)
No neoadjuvant 75 (88%)
Stage
Stage I, II 24 (28%)
Stage III, IV 61 (72%)
Tumor grade
Low grade (1/2) 56 (66%)
High grade (3) 29 (34%)
Abbreviations: PDAC pancreatic ductal adenocarcinoma;
SD standard deviation, LVI lymphovascular invasion;
LN lymph node, PNI perineural invasion
Table 2 Overall survival and clinicopathological variables in 85
patients with PDAC
Variables Hazard ratio (95% CI) p-value
Univariate analysis
Age (< 65 vs ≥65) 0.98 (0.59–1.62) .94
Gender (male vs. female) 1.13 (0.68–1.88) .65
Tumor size (< 2 cm vs. ≥ 2 cm) 2.11 (1.07–4.16) .03
Stage (I/II vs. III/IV) 0.74 (0.44–1.26) .28
Grade (low vs. high) 1.84 (1.11–3.05) .02
PNI 1.18 (0.70–2.01) .54
LVI 1.46 (0.90–2.40) .13
LN metastasis 1.31 (0.77–2.21) .32
HNF-1B (negative vs. positive) 1.34 (0.70–2.57) .38
No neoadjuvant 1.14 (0.41–1.14) .80
Multivariate analysis
Tumor size (< 2 cm vs. ≥ 2 cm) 2.10 (1.06–4.16) .03
Grade (low vs. high) 1.83 (1.10–3.06) .02
Abbreviations: PDAC, pancreatic ductal adenocarcinoma; VS, versus;
SD standard deviation, LVI lymphovascular invasion;
LN lymph node, PNI perineural invasion
Bold: Statistically significant
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cytoplasmic staining in 64 (59.8%) cases (Fig. 3a), nuclear
staining in 32 (29.9%) cases (Fig. 3b), nuclear and cyto-
plasmic staining in 6 (5.6%) cases (Fig. 3c), and cytoplas-
mic and membranous staining in 5 (4.7%) cases (Fig. 3d).
Among the 107 HNF-1B positive PDAC cases, 90 cases
(70.9%) showed strong staining, while 17 (13.4%) showed
weak staining pattern. There was no significant associ-
ation of HNF-1B staining pattern or intensity with cyto-
plasmic clearing of the tumor cells.
Sixteen of 17 (94.1%) metastatic PDACs were positive
for HNF-1B, including 13 cases (76.5%) with strong
staining and 3 cases (17.6%) showed weak staining.
Interestingly, 12 metastatic PDACs (70.6%) showed pre-
dominantly nuclear immunoreactivity with or without
cytoplasmic staining (Fig. 3e, f ).
HNF-1B expression in non-pancreatic carcinomas
In order to investigate whether HNF-1B protein expres-
sion was restricted to the adenocarcinomas of pancreatic
ductal origin, HNF-1B IHC was performed on a total of
278 common carcinomas from other organ systems,
including cholangiocarcinoma (intrahepatic and extrahe-
patic biliary tracts), ampullary region, gallbladder, color-
ectum, distal esophagus, stomach, hepatocellular, lung
adenocarcinoma, lung squamous cell carcinoma, breast,
prostate, ovary, uterus, bladder urothelial, and kidney.
Not surprisingly, HNF-1B was strongly immunoreactive
with nuclear and/or cytoplasmic patterns in 13 of 15
(86.7%) intrahepatic and extrahepatic cholangiocarcinomas,
13 of 18 (72.2%) ampullary adenocarcinomas, and 13 of 14
(92.9%) gallbladder adenocarcinomas. In addition, strong
nuclear immunoreactivity of HNF-1B was observed in 16
of 21 (76.1%) clear cell carcinomas of the kidney, 10 of 14
(71.4%) ovarian clear cell carcinomas, 6 of 24 (25%) lung
adenocarcinomas, and 4 of 15 (26.7%) prostate adenocar-
cinomas. Weak nuclear with or without cytoplasmic
HNF-1B expression was seen in 3 of 11 (27.3%) esophageal
adenocarcinomas, 9 of 14 (64.3%) stomach adenocarcin-
omas, 7 of 18 bladder urothelial (38.9%), and 10 of 21
(42.8%) non-clear cell type Müllerian carcinomas. HNF-1B
was completely negative in all colorectal cancer, breast can-
cer, hepatocellular carcinoma, and lung squamous cell
Fig. 1 HNF-1B expression pattern by IHC in non-neoplastic pancreaticobiliary epithelium, including (a) Pancreas, (b) Gallbladder, and (c)
intrahepatic bile duct. Original magnification, 200×
Fig. 2 Histomorphological variation of PDAC on hematoxylin and eosin (HE) staining, including (a) conventional, (b) clear cell variant, and (c)
mixed features. Original magnification, 400×
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Fig. 3 Variable expression pattern of HNF-1B by IHC in primary and metastatic PDACs. (a) Primary PDAC with cytoplasmic staining, (b) Primary
PDAC with nuclear staining, (c) Primary PDAC with nuclear and cytoplasmic staining, (d) Primary PDAC with cytoplasmic and membranous
staining, (e) Metastatic PDAC with nuclear staining, and (f) Metastatic PDAC with cytoplasmic staining. Original magnification, 400×
Table 3 Immunoreactivity of HNF-1B in PDAC and non-pancreatic carcinomas
Cancer type Total No. HNF-1B + Stain pattern Fisher’s exact p-value
Pancreatic primary 127 107 (84.3%) C, N, M ref
Cholangiocarcinoma 15 13 (86.7%) C, N, M .81
Ampullary 18 13 (72%) C, N, M .21
Gallbladder 14 13 (92.9%) C, N, M .69
Colorectal 39 0 – <.001
Hepatocellular 20 0 – <.001
Esophagus 11 3 (27.3%) C, N <.001
Stomach 14 9 (64.3%) C, N .13
Lung adenocarcinoma 24 6 (25%) C, N <.001
Lung Squamous cell 10 0 – <.001
Breast 20 0 – <.001
Bladder 18 7 (38.9%) C, N <.001
Prostate 15 4 (26.7%) C, N <.001
Kidney 21 16 (76.2%) N .35
Ovary 18 14 (77.8%) N, C .50
Uterus 21 10 (47.6%) N, C <.001
Metastatic PDAC 17 16 (94.1%) N, C
Total No. 422
Abbreviations: PDAC, pancreatic ductal adenocarcinoma;
SCC squamous cell carcinoma, C cytoplasmic, N nuclear, M membranous
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carcinoma (Table 3). Fisher’s exact tests showed signifi-
cantly lower HNF-1B expression rate in the colorectal, he-
patocellular, esophageal, lung, breast, bladder, prostate, and
uterine carcinomas (P < .001, Table 3).
Sensitivity and specificity of HNF-1B in pancreaticobiliary
carcinomas
Since we observed that HNF-1B was expressed in the ma-
jority of carcinomas arising from the pancreatic and biliary
epithelium, we calculated the sensitivity, specificity, posi-
tive predictive value, negative predictive value, and accur-
acy with 95% confidence interval (95% CI) of HNF-1B for
all primary pancreaticobiliary carcinomas in comparison
to non-pancreaticobiliary carcinomas. The results were
summarized in Table 4. Overall, HNF-1B showed high
sensitivity (84%) and high negative predictive value (85%)
for primary pancreaticobiliary carcinomas with moderate
specificity and accuracy (68 and 75%, respectively).
Discussion
We investigated the protein expression pattern of
HNF-1B in 127 primary PDACs, 47 biliary adenocarcin-
omas, 17 metastatic PDACs, and 231 other common
carcinomas that may mimic PDAC. HNF-1B was highly
expressed in adenocarcinomas along the pancreaticobili-
ary tract, including PDAC, intrahepatic and extrahepatic
cholangiocarcinomas, ampullary adenocarcinomas, and
gallbladder adenocarcinomas with nuclear and/or cyto-
plasmic staining pattern. Importantly, HNF-1B expres-
sion was expressed in 94.1% of metastatic PDAC with
predominantly nuclear staining.
KRAS mutation is a frequent molecular abnormality
that is identified in up to 90% of PDACs [20]. Interest-
ingly, a recent study showed that mutated KRAS can in-
duce abnormal regulations of pancreatic transcription
factors including HNF-1B, which in turn causes abnormal
cell growth and proliferation that leads to pancreatic can-
cer [21]. These findings were consistent with the funda-
mental pathophysiological role of HNF-1B in the
pancreaticobiliary system. The other group has also re-
ported cytoplasmic and/or nuclear expression of HNF-1B
in PDAC [18]. Although transcription factors are trans-
lated in the cytoplasm, they are generally translocated into
the nucleus to regulate downstream target genes in
active physiological state. During inactive regulation
or with aberrantly excessive expression, transcription
factors may form complex with other proteins and re-
main in the cytoplasm and/or cell membrane. This
might explain why HNF-1B showed variable nuclear,
cytoplasmic and/or membranous staining patterns in
PDAC and other carcinomas.
Among non-pancreaticobiliary carcinomas, clear cell
carcinomas of the kidney showed predominantly nuclear
HNF-1B expression, while Müllerian origin, including
ovarian and endometrial clear cell carcinoma showed
nuclear and/or cytoplasmic HNF-1B expression. The ex-
pression of HNF-1B in carcinomas of kidney and Mül-
lerian origin also indicates its pathophysiological role in
these organs. Interestingly, silencing of HNF-1B expres-
sion secondary to promoter methylation appears to pro-
mote disease progression via epithelial-to-mesenchymal
transition in both prostate and ovarian cancers [22]. In
contrast to the association of HNF-1B with poor prog-
nosis in PDAC observed by Kim et al. [18], HNF-1B
seemed to have tumor-suppressor role in both prostate
and kidney cancers [22, 23]. Thus, a biological role(s) of
HNF-1B as well as the significance of its aberrant cyto-
plasmic and membranous expressions in different types
of cancer needs to be investigated in the future.
Conclusions
Our data suggested that HNF-1B may serve as a useful
diagnostic biomarker for tumors of the pancreaticobiliary
origin with high sensitivity and negative predictive value,
but moderate specificity and accuracy for these tumors.
Since HNF-1B can also be expressed less frequently in
variable tumors of the non-pancreaticobiliary origin, espe-
cially of the kidney, Müllerian tract, lung, gastroesopha-
geal, bladder, and prostate carcinomas, the concurrent use
of other markers such as TTF-1, PAX-8, WT-1, CAIX,
NKX3.1, p40, and PSA as a panel to rule out other organ
primaries, and correlation with imaging studies and/or
endoscopic findings are important to refine the diagnosis.
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